Intracoronary brachytherapy

Patients presenting with in‐stent restenosis have an increased risk of need for repeat intervention. Intracoronary brachytherapy is indicated for these patients to prevent recurrent in‐stent restenosis. Three intravascular brachytherapy systems are currently FDA‐approved for use in patients: one uti...

Full description

Saved in:
Bibliographic Details
Published in:Catheterization and cardiovascular interventions 2002-06, Vol.56 (2), p.281-288
Main Authors: Nguyen-Ho, Phong, Kaluza, Grzegorz L., Zymek, Pawel T., Raizner, Albert E.
Format: Article
Language:English
Subjects:
angioplasty
Beta Particles
Biological and medical sciences
brachytherapy
Brachytherapy - adverse effects
Brachytherapy - methods
coronary
Coronary Restenosis - prevention & control
Coronary Restenosis - radiotherapy
Coronary Vessels
Diseases of the cardiovascular system
Gamma Rays
Humans
Medical sciences
Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)
Recurrence
restenosis
Retreatment
stent
Stents
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients presenting with in‐stent restenosis have an increased risk of need for repeat intervention. Intracoronary brachytherapy is indicated for these patients to prevent recurrent in‐stent restenosis. Three intravascular brachytherapy systems are currently FDA‐approved for use in patients: one utilizing gamma‐radiation (Cordis) and two using beta‐radiation (Novoste and Guidant). Current evidence and labeling do not support using intracoronary brachytherapy for prevention of restenosis in de novo lesions. Brachytherapy is absolutely contraindicated in patients unable to take prolonged combination antiplatelet drugs. Aspirin and a thienopyridine should be taken for 6 months if no new stent is placed and 12 months if a new stent is placed. If possible, new stent implementation should be avoided. Cathet Cardiovasc Intervent 2002;56:281–288. © 2002 Wiley‐Liss, Inc.
ISSN:1522-1946
1522-726X
DOI:10.1002/ccd.10260